Entrectinib: A New Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusionpositive, Recurrent or Advanced Solid Tumors
| Autor: | Meral Tuncbilek, Hind M Osman |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Drug
Adult Indazoles Lung Neoplasms medicine.drug_class media_common.quotation_subject Entrectinib Tropomyosin receptor kinase A Biochemistry Tyrosine-kinase inhibitor Proto-Oncogene Proteins Drug Discovery medicine ROS1 Humans Child Protein Kinase Inhibitors media_common Pharmacology business.industry Organic Chemistry Receptor Protein-Tyrosine Kinases Protein-Tyrosine Kinases Clinical trial Mechanism of action Benzamides Cancer research Molecular Medicine medicine.symptom business Tyrosine kinase |
| Zdroj: | Current medicinal chemistry. 29(15) |
| ISSN: | 1875-533X |
| Popis: | Background: Entrectinib is a highly potent ATP-competitive and selective inhibitor of tyrosine kinases - Trk A B C, ALK, and ROS1. It was developed by Roche and initially approved in Japan in 2019 to treat pediatric and adult patients with NTRK fusionpositive, recurrent, or advanced solid tumors. In August 2019, entrectinib received accelerated approval by the U.S FDA for this indication. It is also the first FDA-approved drug designed to target both NTRK and ROS1. Objective: We aim to summarize recent studies related to the synthesis, mechanism of action, and clinical trials of the newly approved selective tyrosine kinase inhibitor entrectinib. Method: We conduct a literature review of the research studies on the new highly-potent small-molecule entrectinib. Conclusion: Entrectinib, based on three clinical studies (ALKA, STARTRK-1, and STARTRK-2), was well tolerated, with a manageable safety profile. It induced clinically meaningful responses in recurrent or advanced solid tumors associated with NTRK fusion- positive or ROS1+ NSCLC. It demonstrated substantial efficacy in patients with CNS metastases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|